Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Sanofi-a Ventis Deutschland Gmbh

Paz Arzneimittelentwicklungsgesellschaft Mbh

Johann Wolfgang Goethe-universitat Frankfurt Am Main

Sanofi-aventis Pharma Gmbh

Pharmatrans Sanaq Ag

Horizon Pharma Ag

Goethe-universität Frankfurt Am Main

Gerd Geisslinger

Martin Michaelis

Klaus Scholich

Kay Brune

Gerhard Jaehne

Olaf Ritzeler

Michael John Parnham

Irmgard Tegeder

Karl Rudolphi

Hans-Georg Schaible

Kurt H Bauer

Andreas Weigert

Christian Brenneis

Javier Mora

Christina Dillmann

Sabine Grösch

Bernhard Brune

Anton S Huber

Marco Sisignano

Sebastian Zinn

Katrin SCHRÖDER

Achim Schmidtko

Bernhard BRÜNE

Marco Sissignano

Bernhard Bruene

Ralf Brandes

Wiebke Kallenborn-Gerhardt

Natasja De Bruin

Stephan Hohmann

Susanne Schiffmann

The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1. In this context the invention proposes to use combinations of CYP2J2 agonist or metabolites and transient receptor potential vanilloid 1 (TRPV1) agonists to treat disorders that respond to TRPV1 agonists, such as neuropathic pain.

CYP2J2 antagonists in the treatment of pain

The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.

N-terminally truncated interleukin-38

The invention relates to the use of a granulin or a granulin-like compound for producing a pharmaceutical composition for the therapy or prophylaxis of chronic pain, in particular for neuropathic pain.

Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain

Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds.

Method for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compounds

The present invention relates to the use of I&#x3ba;B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

Use of I&#x3ba;B-kinase inhibitors in pain therapy

Use of a granulin or a granulin-like compound in the therapy or prophylaxis of chronic pains

The invention relates to the use of R-enantiomers of arylpropionic acids or the pharmacologically acceptable salts or derivatives thereof, in a pure or enriched form in contrast to the racemic compound, for the production of medicaments which inhibit the activation of nuclear transcription factor AP-1 and which are suitable for treating illnesses which are influenced by said factor.

Use of R-arylpropionic acids for treating illnesses with a rheumatic nature

The present invention relates to a method for the prophylaxis or treatment of pain using compounds of formula I, in which R, R2, R3, R4 and R5 have the meanings indicated in the specification.

2-amino-1,3-propanediol compounds for the treatment of acute pain

2-arylpropionic acid preparations and process for their production

The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the previously separated enantiomers of flurbiprofen are worked up in a ratio of 99.5-0.5% to 0.5-99.5%, in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.

Medicament and its production and use in the treatment of pain,

The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the flurbiprofen is pure or preponderantly R(-)-flurbiprofen worked up in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.

Growing community of inventors

Bad Soden, Germany

Gerd Geisslinger